WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsStandard Biotools Inc (LAB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 24071% more annual revenue ($20.63B vs $85.33M). GEHC leads profitability with a 10.1% profit margin vs -87.8%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

LAB

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for LAB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

LAB1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

LAB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$379.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-13.1%2/10

ROE of -13.1% — below average capital efficiency

Revenue GrowthGrowth
-14.2%2/10

Revenue declined 14.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : LAB

The strongest argument for LAB centers on Price/Book.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : LAB

The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

GEHC profiles as a value stock while LAB is a turnaround play — different risk/reward profiles.

LAB carries more volatility with a beta of 1.37 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Standard Biotools Inc

HEALTHCARE · MEDICAL DEVICES · USA

Standard Biotools Inc. (LAB) is a leading biotechnology firm committed to advancing the capabilities of genomic analysis and biological research through innovative tools and technologies. The company specializes in high-performance products designed specifically for laboratories focused on genomics and proteomics, significantly improving research accuracy and efficiency. By leveraging proprietary platforms, Standard Biotools empowers scientists to accelerate their discoveries and enhance the quality of their work. With a strategic position within the dynamic biotechnology landscape, LAB is poised to meet the rising demand for sophisticated analytical solutions vital to the life sciences industry.

Want to dig deeper into these stocks?